The article discusses limitations of current sepsis diagnosis, the potential role of emerging biomarkers in risk stratification, and challenges in translating biomarker science into clinical workflows.
Approach:
Current diagnosis: Clinicians rely on clinical observations and blood tests that typically identify inflammation. When infection is suspected, microbiological testing may be initiated; blood culture and organism identification can be accurate and guide antibiotic selection, but may take 48 hours or more.
Biomarker under investigation: MicrosensDx is developing a diagnostic test based on the ratio of oxidized to total pentraxin 3 (PTX3). The interviewees describe published research associating higher ratios with more severe sepsis and a decline in the ratio as patients improve.
Key Findings:
Sepsis symptoms are varied and nonspecific, and routine inflammation tests may not distinguish a dangerous trajectory from other causes of inflammation.
The interviewees report that published research found higher oxidized-to-total PTX3 ratios associated with more severe sepsis, with ratios appearing to decline as patients improve.
The interviewees describe serial PTX3 measurements as a possible way to assess sepsis risk and monitor disease course or response to treatment; MicrosensDx is developing a diagnostic test.
Interpretation:
The interview presents oxidized-to-total PTX3 as a candidate biomarker for risk stratification and monitoring, potentially used alongside clinical findings and microbiological testing.
Limitations:
The article does not provide study design, sample size, or quantitative performance estimates for the cited PTX3 research.
The source describes the PTX3 diagnostic test as under development.
The interviewee says the specificity of CRP, lactate, and procalcitonin in early undifferentiated presentations remains debated.
Conclusion:
The interviewees describe a need for earlier, more specific sepsis assessment and present oxidized-to-total PTX3 as a biomarker under investigation for that purpose.
